M Romeu1, C Couchoud1, J-C Delarozière1, S Burtey1, L Chiche1, J-R Harlé1, B Gondouin1, P Brunet1, Y Berland1, N Jourde-Chiche2. 1. From the Department of Nephrology, Hopital Conception, AP-HM, Aix-Marseille Université, 147 Bd Baille, 13385 Marseille Cedex 5, Agence de la Biomédecine, Registre REIN, 1 avenue du Stade de France, 93212 Saint-Denis-La Plaine, France, Department of Public Health, Hopital Timone, AP-HM, Aix-Marseille Université, 27 Bd Jean Moulin, 13385 Marseille Cedex 5 and Department of Internal Medicine, Hopital Conception, AP-HM, Aix-Marseille Université, 147 Bd Baille, 13385 Marseille Cedex 5, France. 2. From the Department of Nephrology, Hopital Conception, AP-HM, Aix-Marseille Université, 147 Bd Baille, 13385 Marseille Cedex 5, Agence de la Biomédecine, Registre REIN, 1 avenue du Stade de France, 93212 Saint-Denis-La Plaine, France, Department of Public Health, Hopital Timone, AP-HM, Aix-Marseille Université, 27 Bd Jean Moulin, 13385 Marseille Cedex 5 and Department of Internal Medicine, Hopital Conception, AP-HM, Aix-Marseille Université, 147 Bd Baille, 13385 Marseille Cedex 5, France noemie.jourde@ap-hm.fr.
Abstract
BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) can lead to end-stage renal disease in patients with renal involvement. OBJECTIVE: This study evaluated the survival of AAV patients on chronic dialysis in France. METHODS: Between 2002 and 2011, a total of 425 AAV patients started chronic dialysis and were registered in the Renal Epidemiology and Information Network. We analysed survival censored for renal transplantation, recovery of renal function and loss to follow-up. AAV patients were compared with 794 matched non-AAV patients on chronic dialysis. RESULTS: A total of 166 (39%) patients with microscopic polyangiitis and 259 (61%) patients with granulomatosis with polyangiitis were registered. Within a median follow-up of 23 months, 58 (14%) patients received a renal allograft and 19 (4%) recovered renal function. Median survival on dialysis was 5.35 years (95% CI, 4.4-6.3) and survival rates at 3 months, 1, 3 and 5 years were 96%, 85%, 68% and 53%, respectively. A total of 143 (41%) patients died after a median of 16 months. Causes of death were cardiovascular (29%), infections (20%), malnutrition (13%), malignancies (4%), AAV relapse (2%), miscellaneous (14%) and unknown (18%). Multivariate logistic regression identified three independent risk factors associated with AAV patients' mortality: age (HR = 1.05/year, P < 0.001), peripheral artery disease (HR = 2.62, P = 0.003) and frailty (HR = 2.43, P < 0.001). Survival of AAV patients did not differ from non-AAV controls, but infectious mortality was higher in AAV patients (20% vs. 8%, P < 0.001). CONCLUSION: Survival of AAV patients in chronic dialysis, although poor, was comparable to survival of non-AAV controls on dialysis. There was a similar burden of cardiovascular mortality, but higher infectious mortality.
BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) can lead to end-stage renal disease in patients with renal involvement. OBJECTIVE: This study evaluated the survival of AAVpatients on chronic dialysis in France. METHODS: Between 2002 and 2011, a total of 425 AAVpatients started chronic dialysis and were registered in the Renal Epidemiology and Information Network. We analysed survival censored for renal transplantation, recovery of renal function and loss to follow-up. AAVpatients were compared with 794 matched non-AAVpatients on chronic dialysis. RESULTS: A total of 166 (39%) patients with microscopic polyangiitis and 259 (61%) patients with granulomatosis with polyangiitis were registered. Within a median follow-up of 23 months, 58 (14%) patients received a renal allograft and 19 (4%) recovered renal function. Median survival on dialysis was 5.35 years (95% CI, 4.4-6.3) and survival rates at 3 months, 1, 3 and 5 years were 96%, 85%, 68% and 53%, respectively. A total of 143 (41%) patients died after a median of 16 months. Causes of death were cardiovascular (29%), infections (20%), malnutrition (13%), malignancies (4%), AAV relapse (2%), miscellaneous (14%) and unknown (18%). Multivariate logistic regression identified three independent risk factors associated with AAVpatients' mortality: age (HR = 1.05/year, P < 0.001), peripheral artery disease (HR = 2.62, P = 0.003) and frailty (HR = 2.43, P < 0.001). Survival of AAVpatients did not differ from non-AAV controls, but infectious mortality was higher in AAVpatients (20% vs. 8%, P < 0.001). CONCLUSION: Survival of AAVpatients in chronic dialysis, although poor, was comparable to survival of non-AAV controls on dialysis. There was a similar burden of cardiovascular mortality, but higher infectious mortality.
Authors: Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig Journal: Z Rheumatol Date: 2017-11 Impact factor: 1.372
Authors: Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2015-06-19 Impact factor: 8.237
Authors: Cristin D W Kaspar; Keia Sanderson; Seza Ozen; Priya S Verghese; Megan Lo; Timothy E Bunchman; Scott E Wenderfer; Jason Kidd Journal: Int J Nephrol Date: 2018-08-05